drugset / Trial / NCT05226507
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Phase 1
Active not recruiting
45 enrolled
Nuvectis Pharma, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT) · collabGynecologic Oncology Group Foundation · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Timeline
- Start
- 2021-12-31
- Primary completion
- 2025-12
- Completion
- 2025-12